Literature DB >> 6502758

Effect of GM1 ganglioside treatment on postlesion responses of cholinergic enzymes in rat hippocampus after various partial deafferentations.

B Oderfeld-Nowak, M Skup, J Ułas, M Jezierska, M Gradkowska, M Zaremba.   

Abstract

The effect of intramuscular administration of monosialoganglioside (GM1) on postlesion responses of choline acetyltransferase and acetylcholinesterase activity in partially deafferented rat hippocampus was studied at various survival times. Lesions partially destroying the medioventral, septal area, or lesions performed in supracallosal stria including corpus callosum and cingulum evoked cholinergic denervation of the hippocampus, while those made in entorhinal cortex resulted in partial glutamatergic deafferentation. GM1 treatment potentiates the responses of both cholinergic enzymes, independently of whether the partial deafferentation was homo- or heterotypical. These data indicate that GM1 may facilitate the regrowth of new cholinergic nerve terminals. However, an effect on other compensatory processes, especially in the first postoperative period, is also possible.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6502758     DOI: 10.1002/jnr.490120225

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  7 in total

1.  Dose-dependent effect of GM1 ganglioside during development on inhibitory avoidance behaviour in mice: influence of the period of administration.

Authors:  S Fagioli; C Rossi-Arnaud; C Castellano
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding.

Authors:  Jay S Schneider; Franca Cambi; Stephen M Gollomp; Hiroto Kuwabara; James R Brašić; Benjamin Leiby; Stephanie Sendek; Dean F Wong
Journal:  J Neurol Sci       Date:  2015-06-16       Impact factor: 3.181

3.  Gangliosides potentiate in vivo and in vitro effects of nerve growth factor on central cholinergic neurons.

Authors:  A C Cuello; L Garofalo; R L Kenigsberg; D Maysinger
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

Review 4.  Ganglioside function in the development and repair of the nervous system. From basic science to clinical application.

Authors:  S D Skaper; A Leon; G Toffano
Journal:  Mol Neurobiol       Date:  1989       Impact factor: 5.590

5.  A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients.

Authors:  Jay S Schneider; Stephen M Gollomp; Stephanie Sendek; Amy Colcher; Franca Cambi; Wei Du
Journal:  J Neurol Sci       Date:  2012-11-28       Impact factor: 3.181

6.  Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinson's Disease.

Authors:  Jay S Schneider; Thomas N Seyfried; Hyo-S Choi; Sarah K Kidd
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

7.  Altered expression of genes involved in ganglioside biosynthesis in substantia nigra neurons in Parkinson's disease.

Authors:  Jay S Schneider
Journal:  PLoS One       Date:  2018-06-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.